5 October 2022 - For post-menopausal women with hormone receptor positive, HER2 negative breast cancer in the first line, there is no survival advantage, but disadvantages in the form of severe side effects - as in the first dossier assessment from 2017.

Palbociclib is approved for use in combination with an aromatase inhibitor for the first-line treatment of post-menopausal patients with hormone receptor positive, HER2 negative, locally advanced or metastatic breast cancer. After an initial early benefit assessment in 2017, the IQWiG has re-examined whether the combination provides an additional clinical benefit compared to the appropriate comparator therapy.

Read IQWiG press release [German]